Comparative study on data set of drug-induced liver injury

doi:10.19803/j.1672-8629.20220447

Abstract

Abstract: Objective To investigate and compare the data sources and methods for risk assessment and drug classification related to DILI so as to provide reference for the construction of DILI datasets and for clinical practice, research and regulation. Methods Five data sets (DILIrank, DICIst, Liver Tox, Suzuki, Greene) that involved more than 300 drugs and assessed the severity of human drug-induced liver injury were selected. The data sources, data volume, DILI risk assessment methods and drug classification were compared and analyzed. Results The data sources included drug labels, literature, network databases, clinical/registration center cases, regulators and other channels. LiverTox involved the largest number of drugs, DILIrank had the highest coincidence with other datasets, and the classification by DILIrank and LiverTox was more detailed. Risk assessment of DILI was classified according to the severity and odds of liver injury. DILI was determined by expert opinions or causal assessment. Conclusion A high-quality data set is related to the data source, data quantity, assessment methods and drug classification. Chinese drug-induced liver injury data sets, especially DILI data sets of Chinese medicines, need to be improved.

Key words: drug-induced liver injury, data set, risk assessment, DILI classification

CLC Number:

R994.11

YAO Keyu, ZHANG Shuqi, JIN Rui, LIU Lihong, ZHU Yan. Comparative study on data set of drug-induced liver injury[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 568-573.

References

[1] YAN B, YE X, WANG J, et al.An algorithm framework for drug-induced liver injury prediction based on genetic algorithm and ensemble learning[J]. Molecules (Basel, Switzerland), 2022, 27(10):3112.
[2] CAO M, WANG L, ZHANG L, et al.Global publication trends and hotspots of molecular biomarkers in DILI from 1991 to 2020: a 30-year bibliometric analysis[J]. Science Progress, 2021, 104(1): 1-16.
[3] CHEN M, WILL Y.Drug-induced liver toxicity[M]. New York, NY: Springer New York, 2018: 45-59.
[4] COLLINS FS, GRAY GM, BUCHER JR.Toxicology,transforming environmental health protection[J]. Science, 2008, 319(5865): 906-907.
[5] CHEN M, SUZUKI A, THAKKAR S, et al.DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans[J]. Drug Discovery Today, 2016, 21(4): 648-53.
[6] CHEN M, VIJAY V, SHI Q, et al.FDA-approved drug labeling for the study of drug-induced liver injury[J]. Drug Discovery Today, 2011, 16(15-16): 697-703.
[7] FDA. Drug Induced Liver Injury Rank (DILIrank) Dataset[DB/OL]. (2022-08-16)[2022-11-17]. https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset.
[8] THAKKAR S, LI T, LIU Z, et al.Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity[J]. Drug Discovery Today, 2020, 25(1): 201-208.
[9] SERRANO J.LiverTox: an online information resource and a site for case report submission on drug-induced liver injury[J]. Clinical Liver Disease, 2014, 4(1): 22-25.
[10] HOOFNAGLE JH, SERRANO J, KNOBEN JE, et al.LiverTox: a website on drug-induced liver injury[J]. Hepatology, 2013, 57(3): 873-874.
[11] JIN RUI, GU HONGVAN, LI LM, et al.Current status of Chinese herbal preparations included in livertox database[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2016, 24(11): 817-823.
[12] NIH. LiverTox: An Online Resource for Information on Drug-induced Liver Injury[EB/OL].(2022-04-01)[2022-07-26]. https://www.niddk.nih.gov/news/archive/2022/livertox-online-resource-information-drug-induced-liver-injury.
[13] NIH. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury[EB/OL]. (2019-05-04)[2022-07-22]. https://www.ncbi.nlm.nih.gov/books/NBK548392/.
[14] SUZUKI A, ANDRADE R J, BJORNSSON E, et al.Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in vigiBase™[J]. Drug Safety, 2010, 33(6): 503-522.
[15] GREENE N, FISK L, NAVEN RT, et al.Developing structure-activity relationships for the prediction of hepatotoxicity[J]. Chemical Research in Toxicology, 2010, 23(7): 1215-1222.
[16] ZIMMERMAN HJ.The Adverse Effects of Drugs and Other Chemicals on the Liver[M]. Philadelphia: Lippincott Williams& Wilkins, 1999.
[17] REGEV A.Drug-induced liver injury and drug development: industry perspective[J]. Seminars in Liver Disease, 2014, 34(2): 227-239.
[18] DILIS V, TRICHOPOULOU A.Assessment of antioxidants in foods and biological samples: a short critique[J]. International Journal of Food Sciences and Nutrition, 2010, 61(5): 441-448.
[19] 39 Health network. China’s first drug-induced liver injury website ‘HepaTox ’ officially released[EB/OL]. (2014-06-17)[2022-07-22]. http://zl.39.net/a/140617/4406784.html.
[20] Chinese Herbs Drug Information. Drug-induced Liver Injury Professional Network[DB/OL]. (2022-03-21)[2022-07-21]. http://www.hepatox.org/chTypeDrug.
[21] Chinese Patent Medicine Drug Information. Drug-induced Liver Injury Professional Network[DB/OL]. (2022-03-21)[2022-07-21]. http://www.hepatox.org/chTypeDrug.
[22] VALL A, SABNIS Y, SHI J, et al.The promise of AI for DILI prediction[J]. Frontiers in Artificial Intelligence, 2021, 4: 638410.